Pharmacokinetics interaction studies between rifampicin and protease inhibitors: Methodological problems

AIDS

Volumn 22, Issue 15, 2008, Pages 2046-2047

  Toibaro, Javier J ^a   Losso, Marcelo H ^a  

^a HOSPITAL RAMOS MEJÍA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CYTOCHROME P450 3A4; GLYCOPROTEIN P; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EXCRETION; DRUG METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIVER TOXICITY; MIXED INFECTION; PATIENT COMPLIANCE; PHARMACOKINETICS; PRIORITY JOURNAL; SIDE EFFECT; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBIOTICS, ANTITUBERCULAR; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; LIVER DISEASES; RESEARCH DESIGN; RIFAMPIN; TUBERCULOSIS;

EID: 53549115340     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283112bb7     Document Type: Letter

References (9)

1. Maher D, Floyd K, Raviglione M. A strategic framework to decrease the burden of TB/HIV. Geneva, Switzerland: World Health Organization; 2002. WHO/CDSATB/2002.296.
2. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001; 344:984-996.
3. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16:75-83.
4. Dear Healthcare Provider letter. Roche Pharmaceuticals; 7 February 2005. http://www.fda.gov/medwatch/SAFETY/2005/safe-ty05.htm#lnvirase. [Accessed 11 February 2005].
5. Nijland HMJ, L'homme RFA, Rongen GA, van Uden P, van Crevel R, Boeree MJ, et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 2008; 22:931-935.
6. la Porte CJL, Colbers EPH, Bertz R, Voncken DS, Wikstrom K, Boeree MJ, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004; 48:1553-1560.
7. Ribera E, Azuaje C, Lopez RM, Domingo P, Curran A, Feijoo M, et al. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. J Antimicrob Chemother 2007; 59:690-697.
8. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Padmapriyadarsini C, Swaminathan S, et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 2004; 48:4473-4475.
9. Losso MH, Lourtau LD, Toibaro JJ, Saenz C, Gonzalez C. The use of saquinavir/ritonavir 1000/100 mg twice daily in patients with tuberculosis receiving rifampin. Antivir Ther 2004; 9:1031-1033.